Regeneron Pharmaceuticals (REGN)
Health Care6 articles
Price chart
Regeneron Pharmaceuticals (REGN) overview
Regeneron is a biotechnology company known for Eylea and Dupixent. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Regeneron Pharmaceuticals trades on the NasdaqGS under the ticker symbol REGN. As of the most recent market data, the stock was priced around $676.69, down 0.33% on the session, giving Regeneron Pharmaceuticals a market capitalization of roughly $70.94B.
Over the past 52 weeks, REGN has traded between $541.00 and $821.11. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 16.5, a common gauge of how richly the market prices the company's earnings. Regeneron Pharmaceuticals also pays a dividend, currently yielding around 56.00%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch REGN
As one of the larger companies in the Health Care sector, Regeneron Pharmaceuticals is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch REGN for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest REGN news
Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Eli Lilly (LLY) and Regeneron (REGN) are among the first seven companies selected for the FDA's PreCheck pilot program aimed at accelerating reviews of new pharmaceutical manufacturing facilities. The initiative allows regulators to review facilities during construction, potentially saving companies up to 14 months in review time. Lilly's facility in Lebanon, Indiana, and Regeneron's $2 billion site in Saratoga Springs, New York, are included in the program. This effort targets domestic drug production and involves companies producing biologic drugs and genetic medicines.
Read More: Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Stocks Moving Premarket: Regeneron, Dominion Energy, Macy's
Premarket trading has seen significant movements for several stocks, including Regeneron, Dominion Energy, and Macy's. Key players in this market include Regeneron Pharmaceuticals, which has recently been the subject of speculation regarding their pipeline. The trading volume and price actions are indicative of investor sentiment ahead of the market open. Understanding these premarket shifts can provide insights into overall market trends and potential impacts on trading for the day.
Read More: Stocks Moving Premarket: Regeneron, Dominion Energy, Macy's
Regeneron (REGN) Stock Drops After Melanoma Drug Trial Failure
Regeneron Pharmaceuticals (REGN) recently reported that its key melanoma drug trial did not achieve the desired outcomes compared to Merck’s Keytruda. This failure is significant as it raises concerns about the effectiveness of Regeneron's treatments in a competitive oncology market. Following the announcement, Regeneron's stock price declined, impacting investor sentiment negatively. The precise percentage drop in stock value was not disclosed, but market reactions generally reflect uncertainty surrounding the company's future drug development prospects.
Read More: Regeneron (REGN) Stock Drops After Melanoma Drug Trial Failure
Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
Regeneron Pharmaceuticals (REGN) posted first-quarter revenue of $3.6 billion, a 19% increase year-over-year, surpassing analysts' expectations of $3.48 billion. Despite a 10% drop in Eylea sales to $941 million, Libtayo sales surged 54% to $438 million, and Dupixent sales reached $1.6 billion, up 36%. The company also initiated a new $3 billion share repurchase program following an $803 million buyback in Q1. Additionally, the FDA granted accelerated approval for Otarmeni, a gene therapy for hearing loss, further enhancing Regeneron's market potential.
Read More: Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Regeneron Pharmaceuticals (REGN) announced its newly approved gene therapy, Otarmeni, will be offered for free in the U.S. while pricing in other countries is still undecided. CEO Leonard Schleifer indicated they are determining a fair price internationally. In clinical trials, 80% of participants saw hearing improvements, with estimates suggesting around 50 babies born annually in the U.S. with the condition. Analysts from Piper Sandler project peak sales of $130 million, emphasizing the limited financial impact due to the condition's rarity.
Read More: Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Regeneron (REGN) drug pricing deal lowers costs, offers free therapy
Regeneron (REGN) agreed to lower U.S. drug prices as part of a deal with President Trump, allowing for the first hearing-loss gene therapy to be offered for free to eligible U.S. patients following FDA approval. This agreement is part of a broader initiative involving 17 deals with pharmaceutical companies aimed at aligning U.S. drug prices with those in other developed nations. Regeneron's gene therapy, Otarmeni, has been projected to achieve peak sales of $130 million, offering significant potential market impact. The deal also includes a three-year exemption from tariffs on pharmaceutical products, which may influence pricing strategies.
Read More: Regeneron (REGN) drug pricing deal lowers costs, offers free therapyMore Health Care stocks
Frequently asked questions
Is Regeneron Pharmaceuticals in the S&P 500?
Yes. Regeneron Pharmaceuticals (REGN) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is REGN in?
Regeneron Pharmaceuticals is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest REGN news?
This page collects recent Regeneron Pharmaceuticals (REGN) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Regeneron Pharmaceuticals's stock price?
As of the most recent market data, Regeneron Pharmaceuticals (REGN) traded at approximately $676.69. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Regeneron Pharmaceuticals's market cap?
Regeneron Pharmaceuticals has a market capitalization of roughly $70.94B, based on its most recent share price and shares outstanding.
What is REGN's P/E ratio?
REGN trades at a trailing price-to-earnings ratio of about 16.5. The P/E ratio compares a company's share price to its earnings per share.